PriceTargets.com logo

Century Therapeutics - IPSC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.60
  • Forecasted Upside: 891.45%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.17 As of 12/17/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for IPSC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Century Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPSC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPSC

Analyst Price Target is $11.60
▲ +891.45% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Century Therapeutics in the last 3 months. The average price target is $11.60, with a high forecast of $24.00 and a low forecast of $5.00. The average price target represents a 891.45% upside from the last price of $1.17.

This chart shows the closing price for IPSC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Century Therapeutics. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024Chardan CapitalLower TargetBuy ➝ Buy$17.00 ➝ $11.00
11/6/2024HC WainwrightLower TargetBuy ➝ Buy$9.00 ➝ $5.00
8/15/2024HC WainwrightLower TargetBuy ➝ Buy$11.00 ➝ $9.00
8/8/2024Rodman & RenshawInitiated CoverageBuy$6.00
6/17/2024Piper SandlerBoost TargetOverweight ➝ Overweight$9.00 ➝ $12.00
6/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/10/2024HC WainwrightLower TargetBuy ➝ Buy$13.00 ➝ $11.00
4/12/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.00
3/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00
3/15/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$22.00 ➝ $24.00
12/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$13.00
8/28/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$28.00 ➝ $5.00
8/10/2023Piper SandlerLower TargetOverweight ➝ Overweight$14.00 ➝ $10.00
8/10/2023HC WainwrightLower TargetBuy ➝ Buy$17.00 ➝ $13.00
8/9/2023Chardan CapitalLower TargetBuy ➝ Buy$19.00 ➝ $17.00
4/17/2023EF Hutton Acquisition Co. IReiterated RatingBuy$16.00
4/13/2023HC WainwrightReiterated RatingBuy$17.00
3/22/2023Chardan CapitalReiterated RatingBuy$19.00
3/17/2023Bank of AmericaLower Target$23.00 ➝ $20.00
3/17/2023HC WainwrightLower TargetBuy$19.00 ➝ $17.00
3/16/2023EF Hutton Acquisition Co. IReiterated RatingBuy$16.00
2/9/2023HC WainwrightReiterated RatingBuy$19.00
1/6/2023Piper SandlerLower TargetOverweight$24.00 ➝ $14.00
1/6/2023Leerink PartnersLower TargetOutperform$20.00 ➝ $14.00
1/6/2023HC WainwrightLower TargetBuy$25.00 ➝ $19.00
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$18.00
12/27/2022Chardan CapitalInitiated CoverageBuy$19.00
11/14/2022HC WainwrightLower TargetBuy$27.00 ➝ $25.00
11/11/2022Piper SandlerBoost TargetOverweight ➝ Overweight$22.00 ➝ $24.00
10/31/2022GuggenheimInitiated CoverageBuy$15.00
10/10/2022Canaccord Genuity GroupInitiated CoverageBuy$28.00
6/10/2022Roth CapitalInitiated CoverageBuy
5/23/2022HC WainwrightInitiated CoverageBuy$27.00
5/16/2022Piper SandlerLower TargetOverweight$38.00 ➝ $22.00
5/12/2022William BlairInitiated CoverageMarket Perform
3/18/2022Leerink PartnersReiterated RatingBuy$32.00
11/19/2021Leerink PartnersLower TargetOutperform$33.00 ➝ $32.00
8/15/2021Leerink PartnersReiterated RatingBuy
7/13/2021Leerink PartnersInitiated CoverageOutperform$33.00
7/13/2021JPMorgan Chase & Co.Initiated CoverageOverweight$40.00
7/13/2021Bank of AmericaInitiated CoverageBuy$34.00
7/13/2021Piper SandlerInitiated CoverageOverweight$38.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/22/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/20/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Century Therapeutics logo
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $1.17
Low: $1.13
High: $1.18

50 Day Range

MA: $1.40
Low: $1.15
High: $1.72

52 Week Range

Now: $1.17
Low: $1.13
High: $5.51

Volume

538,799 shs

Average Volume

310,335 shs

Market Capitalization

$99.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Century Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Century Therapeutics in the last year: Canaccord Genuity Group Inc., Chardan Capital, HC Wainwright, Piper Sandler, and Rodman & Renshaw.
View the latest analyst ratings for IPSC.

What is the current price target for Century Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Century Therapeutics in the last year. Their average twelve-month price target is $11.60, suggesting a possible upside of 891.5%. Canaccord Genuity Group Inc. has the highest price target set, predicting IPSC will reach $24.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Century Therapeutics in the next year.
View the latest price targets for IPSC.

What is the current consensus analyst rating for Century Therapeutics?

Century Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IPSC will outperform the market and that investors should add to their positions of Century Therapeutics.
View the latest ratings for IPSC.

What other companies compete with Century Therapeutics?

Other companies that are similar to Century Therapeutics include Cryoport, Procaps Group, Neurogene, biote and Voyager Therapeutics. Learn More about companies similar to Century Therapeutics.

How do I contact Century Therapeutics' investor relations team?

The company's listed phone number is 267-817-5790 and its investor relations email address is [email protected]. The official website for Century Therapeutics is www.centurytx.com. Learn More about contacing Century Therapeutics investor relations.